share_log

Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval

Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval

兴奋:底特律将迷幻药合法化,Compass研究裸盖菇素治疗创伤后应激障碍,长丝首次获得FDA批准
Benzinga Real-time News ·  2021/11/08 23:54

Detroit Decriminalizes Psychedelics

底特律将迷幻药合法化

Detroit is the latest to join the growing list of U.S. cities that have decriminalized psychedelic substances.

底特律是最新加入到越来越多的美国城市名单中的城市使致幻物质合法化。

The measure under which the Motor City will “decriminalize to the fullest extent permitted under Michigan law the personal possession and therapeutic use of entheogenic plants by adults,” received approximately 62% votes in favor and 38% against, reported Marijuana Moment.

据大麻时刻报道,汽车城将“在密歇根州法律允许的最大程度上将成年人个人拥有和治疗性使用灵媒植物合法化”的措施获得了大约62%的赞成票和38%的反对票。

Under the new policy, “the personal possession and therapeutic use of entheogenic plants by adults” would be considered among Detroit’s “lowest law-enforcement priority.”

根据新政策,“成年人个人拥有和治疗性使用催生植物”将被视为底特律“最低的执法优先事项”之一。

In October Seattle became the largest U.S. city to decriminalize psychedelic substances. Other cities that have decriminalized some or all entheogens include Oakland and Santa Cruz, California; Denver, Colorado and Ann Arbor, Michigan. 

今年10月,西雅图成为美国最大的将迷幻物质合法化的城市。其他已经将部分或全部诱因合法化的城市包括加利福尼亚州的奥克兰和圣克鲁斯,科罗拉多州的丹佛和密歇根州的安娜堡。

California made headlines several times this year concerning its psychedelics decriminalization bill, which has already passed several committees.

加州今年几次因其迷幻药非刑事化法案而登上头条,该法案已经通过了几个委员会。

Filament Health To Launch First U.S. Trial Using Plant-derived Psychedelics

灯丝健康公司将在美国推出首个使用植物性致幻剂的试验

Psychedelic drug discovery company Filament Health Corp. (OTCQB:FLHLF)(NEO: FH) obtained FDA approval to start the first ever clinical trial using naturally-sourced psychedelic substances in the U.S.  

迷幻药物研发公司长丝保健公司OTCQB:FLHLF)(NEO:FH)获得FDA批准,在美国开展首次使用天然来源迷幻药物的临床试验。

The phase 1 trial has been designed to include 20 healthy subjects and will examine the effects of Filament’s three proprietary botanical drug candidates: PEX010 (oral psilocybin), PEX020 (oral psilocin) and PEX030 (sublingual psilocin).

第一阶段的试验设计包括20名健康受试者,将检验长丝公司的三种候选植物专利药物的疗效:PEX010(口服裸盖菇素)、PEX020(口服裸盖菇素)和PEX030(舌下裸盖菌素)。

“Our innovative technology has allowed us to create IP-protected botanical drug candidates of oral psilocin, sublingual psilocin, and oral psilocybin, and to enter them into an FDA-approved natural psychedelic clinical trial. Our candidates enjoy significant IP protection, unlike most other psychedelics currently under clinical investigation,” CEO Benjamin Lightburn said.

我们的创新技术使我们能够创造口服裸盖菇素、舌下裸盖菇素和口服裸盖菇素等受知识产权保护的植物药物候选药物,并使它们进入FDA批准的天然迷幻临床试验。我们的候选人享有显著的知识产权保护,不像目前正在接受临床研究的大多数其他迷幻药。“首席执行官本杰明·莱特伯恩说。

Compass To Launch Phase 2 Trial On Psilocybin For PTSD

Compass将启动裸盖菇素治疗创伤后应激障碍的第二阶段试验

Shares from Compass Pathways (NASDAQ:CMPS) are soaring in anticipation of the data being created by the company’s phase 2 trial with psilocybin.

共享自指南针路径纳斯达克(Standard Chartered Bank:CMPS)股价飙升,因为预计该公司使用裸盖菇素进行的第二阶段试验将产生数据。

Adding to the excitement, Compass announced on Wednesday the launch of a new program using psilocybin in the treatment of post-traumatic stress disorder.

更让人兴奋的是,Compass周三宣布推出一项使用裸盖菇素治疗创伤后应激障碍的新计划。

Compass is expected to release data from its depression study in the coming weeks. Anticipation for the announcement led the company’s stock to rise 55% in the last month, posting $49 per share at market close on Friday.

Compass预计将在未来几周公布其抑郁症研究的数据。对这一声明的预期导致该公司股价在上个月上涨了55%,上周五收盘时每股上涨49美元。

With this new announcement, the company is taking its proprietary version of synthetic psilocybin, COMP360, to 20 patients in a safety and tolerability study of psilocybin therapy for people who suffer from PTSD resulting from trauma experienced as adults.

随着这一新的宣布,该公司将把其专利版本的合成裸盖菇素COMP360带给20名患者。裸盖菇素治疗创伤后应激障碍的安全性和耐受性研究是成年人经历的创伤造成的。

The study will begin at The Institute of Psychiatry, Psychology & Neuroscience at King’s College London. Participants will receive a single 25mg dose of COMP360, given in conjunction with specialist psychological support.

这项研究将在伦敦国王学院的精神病学、心理学和神经科学研究所开始。参与者将获得单剂25毫克的COMP360,并与专家心理支持一起给予。

“The primary endpoint of the study is to assess the safety of COMP360 psilocybin therapy. Secondary endpoints will measure efficacy in improving PTSD symptoms, functionality, and quality of life,” noted a company press release.

这项研究的主要终点是评估COMP360裸盖菇素疗法的安全性。次级终端将衡量在改善创伤后应激障碍症状、功能和生活质量方面的有效性。“

Bright Minds Biosciences To Join ‘Nasdaq Psychedelic Group’

博智生物科学公司将加入“纳斯达克致幻集团”

Bright Minds Biosciences (CSE:DRUG) received approval on Wednesday to list its stock on the Nasdaq starting Monday, November 8 under the symbol “DRUG.”

聪明人生物科学(CSE:DICAL)周三获得批准,将于11月8日(星期一)开始在纳斯达克上市,股票代码为“DUSIC”。

The company is developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain by using psychedelics-derived molecules.

该公司正在开发使用迷幻药衍生分子靶向治疗神经精神障碍、癫痫和疼痛的新药。

“With encouraging preclinical data across several indications, we are progressing toward first-in-human trials with our lead drug candidate, BMB-101, for the treatment of Dravet syndrome, a devastating congenital and genetic disease affecting the nervous system. We expect to commence the trials in the first half of 2022,” said Ian McDonald, CEO and co-founder of Bright Minds Biosciences. 

“有了令人鼓舞的几个适应症的临床前数据,我们正在与我们的主要候选药物进行首次人体试验,BMB-101,用于治疗德拉韦氏综合症,这是一种影响神经系统的破坏性先天性和遗传性疾病。我们预计在2022年上半年开始试验。伊恩·麦克唐纳Bright Minds Biosciences的首席执行官兼联合创始人。

Bright Minds has a portfolio of next-generation serotonin agonists (compounds similar to LSD, psilocybin and DMT) designed to target neurocircuit abnormalities that are responsible for disorders such as resistant epilepsy, treatment-resistant depression, PTSD and pain.

Bright Minds拥有一系列下一代5-羟色胺激动剂(类似于LSD、psilocybin和DMT的化合物),旨在针对导致难治性癫痫、难治性抑郁症、创伤后应激障碍和疼痛等疾病的神经回路异常。

Its lead drug candidate, BMB-101, has demonstrated compelling activity in in-vitro and in-vivo non-clinical tests, reported the company.

据该公司报道,其主要候选药物BMB-101在体外和体内非临床试验中显示出令人信服的活性。

Cybin Gets DEA License To Work With Scheduled Psychedelic Molecules

Cybin获得DEA许可证,可以使用预定的迷幻分子

Cybin Inc. (NYSE:CYBN) has received a Schedule I manufacturing license from the U.S. Drug Enforcement Agency (DEA).

Cybin Inc.(纽约证券交易所股票代码:CYBN)已获得美国禁毒署(DEA)的附表I生产许可证。

The DEA license is a federal requirement for any investigators intending to study, produce or analyze Schedule I substances. Before obtaining the license, Cybin conducted much of its R&D work through globally-licensed research organizations in the U.S., Canada, the U.K. and through certain in-house capabilities.

DEA许可证是联邦政府对任何打算研究、生产或分析附表I物质的调查人员的要求。在获得许可之前,Cybin通过美国、加拿大、英国的全球特许研究机构和某些内部能力进行了大部分研发工作。

“With the DEA license, the company will be able to vastly expand its internal R&D capabilities to support innovative drug discovery and delivery involving Schedule I compounds,” the company announced in a press release.

该公司在一份新闻稿中宣布:“有了DEA许可证,该公司将能够极大地扩大其内部研发能力,以支持涉及附表I化合物的创新药物发现和交付。”

“We are pleased with the progression of our clinical and regulatory efforts since the company's formation,” said CEO Doug Drysdale. "This new license further positions the company as a truly integrated biopharmaceutical company that can continue to work towards progressing psychedelics to therapeutics.”

首席执行官说:“自公司成立以来,我们对我们的临床和监管工作取得的进展感到高兴。”道格·德赖斯代尔。这一新的许可证进一步将该公司定位为一家真正一体化的生物制药公司,可以继续致力于将迷幻药转化为治疗药物。“

The Milestone Round

里程碑式的一轮

PharmaTher Holdings Ltd. (CSE:PHRM) (OTCQB:PHRRF) has entered into a research collaboration agreement with Revive Therapeutics Ltd. (OTCQB:RVVTF) (CSE:RVV) to evaluate the delivery of psilocybin with PharmaTher’s proprietary microneedle patch technology for neuropsychiatric disorders.

PharmaTher Holdings Ltd.(CSE:PHRM)(场外市场代码:PHRRF)已与复兴治疗有限公司。(场外交易代码:RVVTF)(CSE:RVV)评估裸盖菇素与PharmaTher专有微针贴片技术治疗神经精神疾病的效果。

Tryp Therapeutics (CSE:TRYP)(OTCQB:TRYPF) has submitted an Investigational New Drug application to the FDA to evaluate its clinical candidate, TRP-8802, in a Phase 2a clinical trial that would investigate the safety and preliminary effectiveness of psilocybin-assisted therapy among patients with fibromyalgia in collaboration with the University of Michigan.
Nova Mentis Life Science Corp. (CSE:NOVA) (OTCQB:NMLSF) announced that the U.S. FDA has approved the company's  Orphan Drug Application for a proprietary version of psilocybin to treat patients with fragile X syndrome (FXS), the most common inherited cause of autism spectrum disorder.

Tryp治疗公司芝加哥商品交易所股票代码:TRYP)(场外交易市场代码:TRYPF)已经向FDA提交了一份研究用新药申请,以评估其临床候选药物Trp-8802,这是一项2a期临床试验,将与密歇根大学合作,调查裸盖菇素辅助治疗纤维肌痛患者的安全性和初步有效性。新曼蒂斯生命科学公司(Nova Mentis Life Science Corp.)纳斯达克股票代码:NOVA)(场外交易市场代码:NMLSF)宣布,美国FDA已批准该公司的孤儿药物申请,用于治疗脆性X综合征(FXS)患者的专利版本裸盖菇素,FXS是导致自闭症谱系障碍的最常见遗传原因。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发